Allergic rhinitis

Overview 
Theory 
Diagnosis 
Management 
Follow up 
Resources 

Last reviewed: 29 Jun 2025

Last updated: 21 Mar 2025

Allergic rhinitis is an immunoglobulin E (IgE)-mediated inflammatory nasal condition resulting from allergen introduction in a sensitised individual.

Presumptive diagnosis of allergic rhinitis is usually clinical and is made if someone experiences one or more of rhinorrhoea, sneezing, itching of nose/palate/eyes, or nasal congestion in response to allergen exposure. Cough is also a common symptom.

The diagnosis is confirmed with demonstration of specific IgE reactive to environmental allergens. Food allergy testing is not recommended in the routine evaluation of rhinitis.

Treatment includes allergen avoidance (reducing exposure to relevant allergens such as dander, dust mite, and pollen), pharmacotherapy, and immunotherapy.

Intranasal corticosteroids remain the single most effective class of medications for treating allergic rhinitis.

Immunotherapy is often recommended for patients with persistent symptoms.

Definição

Allergic rhinitis (AR) is an immunoglobulin E (IgE)-mediated inflammatory nasal condition resulting from allergen exposure in a sensitised individual. AR is a common inflammatory condition of the upper respiratory tract, characterised by nasal pruritus, sneezing, rhinorrhoea, and nasal congestion. Frequently, there is associated palate, throat, ear, and eye itching as well as eye redness, puffiness, and watery discharge.

AR may sometimes be due to occupational or hobby exposures to proteins that do not commonly provoke IgE-mediated responses. Examples include woodworkers becoming sensitised to wood dusts, or food service workers becoming sensitised to grain dusts.

História e exame físico

Principais fatores diagnósticos

presence of risk factors
sneezing
nasal pruritus

Detalhes completos

Outros fatores diagnósticos

palate, throat, ear, and eye itching
eye redness, puffiness, and watery discharge
fatigue and irritability
nasal congestion
rhinorrhoea
allergic shiners
conjunctival injection
ocular mucoid discharge
nasal crease
pale nasal mucosa
swelling of the nasal mucosa and turbinates
abundant clear nasal secretions
Dennie-Morgan lines (creases present under the lower eyelids)

Detalhes completos

Fatores de risco

other atopic conditions or family history of atopy
age <20 years
exposure to aeroallergens (pollen, moulds, house dust mites, pollution)
exposure to animal dander
ethnicity
positive allergen skin-prick tests

Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

therapeutic trial of antihistamine or intranasal corticosteroid

Detalhes completos

Investigações a serem consideradas

allergen skin-prick testing
in vitro specific IgE determination

Detalhes completos

Algoritmo de tratamento

AGUDA

mild or intermittent symptoms

persistent and moderate to severe symptoms

CONTÍNUA

usual therapy ineffective or poorly tolerated

Colaboradores

Autores

Gary C. Steven, MD, PhD, CPI, FAAAAI, FACAAI, FAPCR

Medical Director

American Academy of Allergy, Asthma & Immunology Registry

Assistant Clinical Professor of Medicine

Medical College of Wisconsin

Adjunct Clinical Instructor

College of Nursing

University of Wisconsin-Milwaukee

Allergy, Asthma & Sinus Center

Milwaukee

Declarações

GCS has taken part in sponsored research for the ALK clinical trial of the house dust mite SLIT tablet for use in paediatric patients. He is a member of the Joint Task Force on Practice Parameters Workgroup on the Allergic Rhinitis Practice Parameter.

Agradecimentos

Dr Gary C. Steven would like to gratefully acknowledge Dr Alexander Greiner, a previous contributor to this topic.

Declarações

AG has received grant/research support from: AstraZeneca; Boehringer Ingelheim; Cephalon Circassia Ltd; Clement Clarke Cytos biotechnology; GlaxoSmithKline; Glenmark Specialty, S.A.; Hoffman-LaRoche/Genentech; HRA/Novartis; Janssen Research & Development; Kalypsys , Inc.; Lupin; Merck; Mylan Pharmaceuticals, Inc.; Nestle (Nestec Ltd); Novartis Ono Pharmaceutical Co., Ltd.; Perrigo; Rigel Pharmaceuticals, Inc.; Roxane Laboratories Inc.; Shionogi Inc.; Sunovion TEVA Branded Pharmaceutical Products; UBC (United Biosource Corporation)/Amgen Pharmaceuticals; and sponsorship for pharmaceutical trials from Allergen Research Corporation/Aimmune Therapeutics, Inc. and AstraZeneca.

Revisores

Mark Davis-Lorton, MD

Clinical Immunology Coordinator

Division of Rheumatology, Immunology and Allergy

Winthrop-University Hospital

Mineola

Declarações

MDL declares that he has no competing interests.

Glenis Scadding, MD

Consultant Allergist/Rhinologist

Allergy & Rhinology Department

Royal National Throat, Nose and Ear Hospital

London

Declarações

GS is a consultant/advisory board member for ALK, Britannia Pharmaceuticals, CMP Therapeutics, Grupo Uriach, GSK, Merck, Sanofi-Aventis, Schering Plough, and UCB. She has received research funds from ALK, GSK, UCB, and Schering Plough. She has given talks for ALK, GSK, Merck, Schering Plough, and UCB and has co-written articles for Schering Plough and GSK.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020 Oct;146(4):721-67.Texto completo Resumo

Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3.Texto completo Resumo

Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (rev ed 2017). Clin Exp Allergy. 2017 Jul;47(7):856-89.Texto completo Resumo

Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018 Feb;8(2):108-352.Texto completo Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.

Diagnósticos diferenciais
- Non-allergic rhinitis
- Acute sinusitis
- Chronic sinusitis
Mais Diagnósticos diferenciais
Diretrizes
- Clinical practice guideline: immunotherapy for inhalant allergy
- Australasian guidelines for allergic rhinitis 2022
Mais Diretrizes
Folhetos informativos para os pacientes
Hay fever
Hay fever: avoiding pollen and mould
Mais Folhetos informativos para os pacientes
Conectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal

Allergic rhinitis

Summary

Definição

História e exame físico

Principais fatores diagnósticos

Outros fatores diagnósticos

Fatores de risco

Investigações diagnósticas

Primeiras investigações a serem solicitadas

Investigações a serem consideradas

Algoritmo de tratamento

mild or intermittent symptoms

persistent and moderate to severe symptoms

usual therapy ineffective or poorly tolerated

Colaboradores

Autores

Gary C. Steven, MD, PhD, CPI, FAAAAI, FACAAI, FAPCR

Declarações

Agradecimentos

Declarações

Revisores

Mark Davis-Lorton, MD

Declarações

Glenis Scadding, MD

Declarações

Referências

Principais artigos

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.

Diagnósticos diferenciais

Diretrizes

Folhetos informativos para os pacientes

Conectar-se ou assinar para acessar todo o BMJ Best Practice

Conectar-se ou assinar para acessar todo o BMJ Best Practice

Conectar-se para acessar todo o BMJ Best Practice